Press release
2017-05-22
The shareholders of Xbrane Biopharma AB (publ) gathered on Thursday 18 may 2017 in Stockholm for the Annual general meeting.
The group’s income statements and balance sheets were adopted and the board of directors and the managing director were granted discharge for the financial year 2016.
The general meeting decided to dispose of the result as proposed by the board in the annual report.
To the board of directors was re-elected Saeid Esmaeilzadeh, Maris Hartmanis, Karin Wingstrand, Peter Edman, Giorgio Chirivi and Alessandro Sidoli. Saeid Esmaeilzadeh was re-elected chairman of the board.
As fees to the board of directors for the period until the next annual general meeting proposed 600 000 sek, of which sek 100,000 to the chairman of the board and sek 100,000 each to the remaining
members.
The accounting firm KPMG AB was re-elected as the company’s auditor, with authorised public accountant, Duane Swanson as chief auditor. The fees to the auditor shall be paid according to approved invoices.
The general meeting decided to authorise the board of directors until the next agm, on one or several occasions, resolve on issues of shares, warrants and/or convertibles, with or without preferential rights for the shareholders to be paid in cash, with capital contributed in kind or by set-off. The authorization may not be used to increase the company’s number of shares by more than 2 000 000 shares.
The general meeting decided, finally, to approve the board’s proposal on directed issue of shares to the par value of a total of 16 500 shares as part of the bonus program for the year 2016 to employees.
About Xbrane
Xbrane Biopharma is a biotechnology company in the commercial phase, which develops and manufactures biosimilar medicinal products and the long-acting injectables. Xbrane has world-leading expertise in the development of long acting injectables, and a patented proteinproduktionsplattform for the development of biosimilar medicinal products. Xbranes head office is in Stockholm and the company has research and development facilities take in Sweden and Italy. Xbrane is listed on Nasdaq First North since 3 February 2016 under the ticker symbol XBRANE and Avanza Bank AB is Xbranes certified adviser. For more information please visit www.xbrane.com.
For further information, please contact:
Martin Åmark, CEO, Xbrane Biopharma AB
M: +46 (0) 763-093 777
E: martin.amark@xbrane.com
Susanna Helgesen, CFO/IR, Xbrane Biopharma AB
M: +46 (0) 708-278 636
E: susanna.helgesen@xbrane.com
Press release – Communiqué from the arsstämma in Xbrane Biopharma AB
